Petra Reinke

Petra Reinke

Auto-generated profile, based on publicly available information

Petra Reinke

Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1997 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
WDWolf-Dietrich Döcke
Wolf-Dietrich Döcke
FRFelix Randow
Felix Randow
USUta Syrbe
Uta Syrbe
DKDietmar Krausch
Dietmar Krausch
KAKhusru Asadullah
Khusru Asadullah
WKWolfgang Kox
Wolfgang Kox

1 October 2009 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CMChristian Meisel
Christian Meisel
JSJoerg C. Schefold
Joerg C. Schefold
RPRene Pschowski
Rene Pschowski
TBTycho Baumann
Tycho Baumann
KHKatrin Hetzger
Katrin Hetzger
HVHans-Dieter Volk
Hans-Dieter Volk
Rationale: Sustained sepsis-associated immunosuppression is associated with uncontrolled infection, multiple organ dysfunction, and death. Objectives: In the first controlled biomarker-guided immunostimulatory trial in sepsis, we tested whether granulocyte–macrophage colony-stimulating factor (GM-CSF) reverses monocyte deactivation, a hallmark of sepsis-associated immunosuppression (primary endpoint), and improves the immunological and clinical course of patients with sepsis. Methods: In a prospective, randomized, double-blind, placebo-controlled, multicenter trial, 38 patients (19/group) with severe sepsis or septic shock and sepsis-associated immunosuppression (monocytic HLA-DR [mHLA-DR] <8,000 monoclonal antibodies (mAb) per cell for 2 d) were treated with GM-CSF (4 μg/kg/d) or placebo for 8 days. The patients' clinical and immunological course was followed up for 28 days. Measurements and Main Results: Both groups showed comparable baseline mHLA-DR levels (5,609 ± 3,628 vs. 5,659 ± 3,332 mAb per cell), which significantly increased within 24 hours in the GM-CSF group. After GM-CSF treatment, mHLA-DR was normalized in 19/19 treated patients, whereas this occurred in 3/19 control subjects only (P < 0.001). GM-CSF also restored ex-vivo Toll-like receptor 2/4–induced proinflammatory monocytic cytokine production. In patients receiving GM-CSF, a shorter time of mechanical ventilation (148 ± 103 vs. 207 ± 58 h, P = 0.04), an improved Acute Physiology and Chronic Health Evaluation-II score (P = 0.02), and a shorter length of both intrahospital and intensive care unit stay was observed (59 ± 33 vs. 69 ± 46 and 41 ± 26 vs. 52 ± 39 d, respectively, both not significant). Side effects related to the intervention were not noted. Conclusions: Biomarker-guided GM-CSF therapy in sepsis is safe and effective for restoring monocytic immunocompetence. Use of GM-CSF may shorten the time of mechanical ventilation and hospital/intensive care unit stay. A multicenter trial powered for the improvement of clinical parameters and mortality as primary endpoints seems indicated. Clinical trial registered with www.clinicaltrials.gov (NCT00252915).

29 October 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DWDimitrios L. Wagner
Dimitrios L. Wagner
LALeila Amini
Leila Amini
DWDesiree J. Wendering
Desiree J. Wendering
LBLisa-Marie Burkhardt
Lisa-Marie Burkhardt
LALevent Akyüz
Levent Akyüz
MSMichael Schmueck-Henneresse
Michael Schmueck-Henneresse

1 February 2019 in Trends in Molecular Medicine
Verified
Journal Article
Open access
Guido MollGuido Moll
Guido Moll
JAJames A Ankrum
James A Ankrum
JKJulian Kamhieh-Milz
Julian Kamhieh-Milz
KBKaren Bieback
Karen Bieback
OROlle Ringdén
Olle Ringdén
PRPetra Reinke
Petra Reinke
Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated that bone marrow MSC infusion is safe. It is not clear if this also applies to diverse new cell products derived from other sources, such as adipose and perinatal tissues. Different MSC products display varying levels of highly procoagulant tissue factor (TF) and may adversely trigger the instant blood-mediated inflammatory reaction (IBMIR). Suitable strategies for assessing and controlling hemocompatibility and optimized cell delivery are crucial for the development of safer and more effective MSC therapies.

1 February 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
RTRalf Trappe
Ralf Trappe
SOStephan Oertel
Stephan Oertel
VLVeronique Leblond
Veronique Leblond
PMPeter Mollee
Peter Mollee
MSMonica Sender
Monica Sender
SCSylvain Choquet
Sylvain Choquet

20 March 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SRSimon Reinke
Simon Reinke
SGSven Geissler
Sven Geissler
William R. TaylorWilliam R. Taylor
William R. Taylor
KSKatharina Schmidt-Bleek
Katharina Schmidt-Bleek
KJKerstin Juelke
Kerstin Juelke
GDGeorg N. Duda
Georg N. Duda
There is growing evidence that adaptive immunity contributes to endogenous regeneration processes: For example, endogenous bone fracture repair is modulated by T cells even in the absence of infection. Because delayed or incomplete fracture healing is associated with poor long-term outcomes and high socioeconomic costs, we investigated the relationship between an individual’s immune reactivity and healing outcome. Our study revealed that delayed fracture healing significantly correlated with enhanced levels of terminally differentiated CD8+ effector memory T (TEMRA) cells (CD3+CD8+CD11a++CD28−CD57+ T cells) in peripheral blood. This difference was long lasting, reflecting rather the individual’s immune profile in response to lifelong antigen exposure than a post-fracture reaction. Moreover, CD8+ TEMRA cells were enriched in fracture hematoma; these cells were the major producers of interferon-γ/tumor necrosis factor–α, which inhibit osteogenic differentiation and survival of human mesenchymal stromal cells. Accordingly, depletion of CD8+ T cells in a mouse osteotomy model resulted in enhanced endogenous fracture regeneration, whereas a transfer of CD8+ T cells impaired the healing process. Our data demonstrate the high impact of the individual adaptive immune profile on endogenous bone regeneration. Quantification of CD8+ TEMRA cells represents a potential marker for the prognosis of the healing outcome and opens new opportunities for early and targeted intervention strategies.